Zydus Lifesciences Limited — Important, 03-06-2025: Agreements

Zydus Lifesciences has announced a board meeting on the financial results for the quarter and half-year. The company entered an exclusive licensing deal with Agenus Inc. for Botensilimab and Balstilimab in India and Sri Lanka. Zydus will lead clinical development and regulatory approvals, paying a 5% royalty on net sales after launch. This deal bolsters Zydus' oncology portfolio, enhancing its presence in immuno-oncology and expanding treatment options across key regional markets.